The United States Patent and Trademark Office (USPTO) has issued US Patent covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.
The patent, titled ”Novel peptides”, provides ATOR-4066 with protection regarding methods of treating cancer and/or a tumor using a bispecific antibody comprising the complementarity-determining regions (CDRs) of the ATOR-4066 molecule.
The first patent of the ATOR-4066 intellectual property portfolio
The patent is the first patent of the ATOR-4066 intellectual property portfolio which is expected to strengthen as more patents are filed and granted. Its accelerated application was part of the Cancer Immunotherapy Pilot program, which provided a fast-track review for cancer immunotherapy-related patent applications in the U.S.
“By simultaneously targeting CD40 and a tumor associated antigen, ATOR-4066 has demonstrated superior anti-tumor immunity, and we see medical opportunities for this first-in-class preclinical asset in , multiple cancer indications, targeting both cold and hot tumor types,” says Søren Bregenholt, CEO of Alligator Bioscience. “The granting of this patent is an important step in the ongoing development of ATOR-4066 and we place great emphasis on the protection of our intellectual property as a key component of our drug development program and our overall business strategy.”
ATOR-4066 was developed by Alligator’s Neo-X-Prime platform that generates bispecific conditional antibody agonists able to significantly boost dendritic cells and T-cell activation by connecting them to tumor debris.
Photo of Søren Bregenholt
